Nardin C, Laheurte C, Puzenat E, Boullerot L, Ramseyer M, Marguier A, Jac- quin M, Godet Y, Aubin F, Adotevi O. Naturally occurring telomerase-specific CD4 T cell immunity in melanoma. J Invest Dermatol. 2021. https:// doi. org/ 10. 1016/j. jid. 2021. 07. 160. 27. Dosset M, Castro A, Carter H, Zanetti M. Telomerase and CD4 T cell immunity in cancer. Cancers (Basel). 2020. https:// doi. org/ 10. 3390/ cance rs120 61687. 28. Ellingsen EB, Mangsbo SM, Hovig E, Gaudernack G. Telomerase as a target for therapeutic cancer vaccines and considerations for optimizing their clini- cal potential. Front Immunol. 2021;12: 682492. 29. Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM. Durable and dynamic hTERT immune responses following vaccination with the long- peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials. J Immunother Cancer. 2022;10: e004345. 30. Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature.